Trial Profile
A Randomized, Double-blind, Multi-center, Parallel Control Phase 3 Study to Compare the Efficacy and Safety of Full Human Anti-TNF Alpha Antibody (HLX03) Versus Adalimumab (Humira®) in Patients With Moderate to Severe Plaque Psoriasis
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 18 May 2022
Price :
$35
*
At a glance
- Drugs Adalimumab (Primary)
- Indications Plaque psoriasis
- Focus Therapeutic Use
- Sponsors Shanghai Henlius Biotech
- 23 Nov 2021 Primary endpoint has been met (Percentage improvement of PASI from baseline to Week 16) , according to Results published in the Advances in Therapy
- 23 Nov 2021 Status changed from recruiting to completed, according to Results published in the Advances in Therapy
- 23 Nov 2021 Results published in the Advances in Therapy